Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Actinium Pharmaceuticals (ATNM) Cash from Investing Activities (2021 - 2025)

Actinium Pharmaceuticals (ATNM) has disclosed Cash from Investing Activities for 6 consecutive years, with -$11000.0 as the latest value for Q1 2024.

  • On a quarterly basis, Cash from Investing Activities rose 85.53% to -$11000.0 in Q1 2024 year-over-year; TTM through Dec 2024 was -$11000.0, a 92.81% increase, with the full-year FY2024 number at -$11000.0, up 92.81% from a year prior.
  • Cash from Investing Activities was -$11000.0 for Q1 2024 at Actinium Pharmaceuticals, up from -$30000.0 in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of -$4000.0 in Q1 2021 to a low of -$270000.0 in Q2 2022.
  • A 4-year average of -$60272.7 and a median of -$47000.0 in 2023 define the central range for Cash from Investing Activities.
  • Peak YoY movement for Cash from Investing Activities: crashed 985.71% in 2023, then skyrocketed 85.53% in 2024.
  • Actinium Pharmaceuticals' Cash from Investing Activities stood at -$68000.0 in 2021, then soared by 76.47% to -$16000.0 in 2022, then crashed by 87.5% to -$30000.0 in 2023, then surged by 63.33% to -$11000.0 in 2024.
  • Per Business Quant, the three most recent readings for ATNM's Cash from Investing Activities are -$11000.0 (Q1 2024), -$30000.0 (Q3 2023), and -$47000.0 (Q2 2023).